A new target therapy to the tumor changed The redeemability of osimertinb for the first-line treatment of lung cancer-small cell with mutation of EGFR is the result of the findings of the study FLAURA in which, for the first time, a therapy has been shown a major advantage in terms of overall survival and progression-free survival”, explains Filippo de Marinis, Director of the Division of Thoracic Oncology at the European Institute of Oncology (IEO) in Milan, italy that speaks of a new standard of care. “An important milestone for patients with lung cancer not to small cells with mutation of EGFR, which may, therefore, access to this treatment soon after diagnosis with benefits in terms of survival but also of safety and tolerability, important elements for the quality of life of patients,” adds Silvia Novello, Professor of Medical Oncology at the Oncology Department of the University of Turin and President of WALCE (Women Against Lung Cancer in Europe – Women Against Lung Cancer in Europe).
In the studio Osimertinib is currently being studied as adjuvant therapy (i.e. for the prevention of recurrences after surgery, study ADAURA), for patients with locally advanced, unresectable disease (study LAURA), in combination with chemotherapy (study FLAURA2) and with other potential new drugs (studies in SAVANNAH and ORCHARD).
"The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence"Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today about Trump, the war declared via Twitter, and the issue of social media with the politicians of the Usa-Iran, a step away from the war Italian soldiers in Libya are ready to evacuation Trump threat, then reconsiders: so messed up its general Crisis-Usa-Iran, the two Wests